Literature DB >> 19637188

Degree of cross-genotype reactivity of hepatitis C virus-specific CD8+ T cells directed against NS3.

Silvia Giugliano1, Filiz Oezkan, Mathias Bedrejowski, Markus Kudla, Markus Reiser, Sergei Viazov, Norbert Scherbaum, Michael Roggendorf, Joerg Timm.   

Abstract

UNLABELLED: The inherent sequence diversity of the hepatitis C virus (HCV) with the existence of multiple genotypes that differ up to 20% at the amino acid level represents one of the major obstacles for immune control. Accordingly, immune control of a heterologous virus challenge, particularly across genotypes, is difficult to achieve; however, the overall role of genotype-specific sequence differences has not yet been defined at the epitope level. The aim of this study was to determine the role of genotype-specific sequence differences for the CD8+ T cell response against HCV. We analyzed a cohort of anti-HCV-positive injection drug users infected with HCV genotype 1 (n = 17) or genotype 3 (n = 22) or undetectable HCV-RNA (n = 14) with overlapping peptides covering consensus sequences of NS3 from both genotypes. Importantly, the majority of HCV-specific CD8 T cells were specific for one genotype only indicating that sequence differences between genotypes are relevant at the epitope level. Interestingly, T cells active against both genotypes were significantly more frequent in HCV-RNA-negative subjects. Of note, we identified five subjects with undetectable viremia and coexistence of two T cell populations-one for each genotype-suggesting immune control of two different genotypes.
CONCLUSION: We systematically analyzed the degree of cross-genotype reactivity of HCV-specific T cells and have shown that CD8 responses targeting different HCV genotypes can be primed in the same individual and that such responses potentially characterize a subgroup among injection drug users being protected from chronic HCV infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19637188     DOI: 10.1002/hep.23096

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  15 in total

1.  Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8+ T Cell Response by Selection of Altered Epitope Processing.

Authors:  Andreas Walker; Kathrin Skibbe; Eike Steinmann; Stephanie Pfaender; Thomas Kuntzen; Dominik A Megger; Svenja Groten; Barbara Sitek; Georg M Lauer; Arthur Y Kim; Thomas Pietschmann; Todd M Allen; Joerg Timm
Journal:  J Virol       Date:  2015-10-07       Impact factor: 5.103

2.  Highly divergent hepaciviruses from African cattle.

Authors:  Victor Max Corman; Adam Grundhoff; Christine Baechlein; Nicole Fischer; Anatoly Gmyl; Robert Wollny; Dickson Dei; Daniel Ritz; Tabea Binger; Ernest Adankwah; Kwadwo Sarfo Marfo; Lawrence Annison; Augustina Annan; Yaw Adu-Sarkodie; Samuel Oppong; Paul Becher; Christian Drosten; Jan Felix Drexler
Journal:  J Virol       Date:  2015-03-18       Impact factor: 5.103

3.  Impact of sequence variation in a dominant HLA-A*02-restricted epitope in hepatitis C virus on priming and cross-reactivity of CD8+ T cells.

Authors:  Susanne Ziegler; Kathrin Skibbe; Andreas Walker; Xiaoyu Ke; Falko M Heinemann; Andreas Heinold; Juk Yee Mok; Wim J E van Esch; Dongliang Yang; Matthias Wölfl; Jörg Timm
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

4.  Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope.

Authors:  Christoph Neumann-Haefelin; Jörg Timm; Julia Schmidt; Nadine Kersting; Karen Fitzmaurice; Cesar Oniangue-Ndza; Michael N Kemper; Isla Humphreys; Susan McKiernan; Dermot Kelleher; Volker Lohmann; Paul Bowness; Daniela Huzly; Hugo R Rosen; Arthur Y Kim; Georg M Lauer; Todd M Allen; Eleanor Barnes; Michael Roggendorf; Hubert E Blum; Robert Thimme
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

5.  Induction of Genotype Cross-Reactive, Hepatitis C Virus-Specific, Cell-Mediated Immunity in DNA-Vaccinated Mice.

Authors:  Danushka K Wijesundara; Jason Gummow; Eric J Gowans; Branka Grubor-Bauk; Yanrui Li; Wenbo Yu; Benjamin J Quah; Charani Ranasinghe; Joseph Torresi
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

6.  Escape from a dominant HLA-B*15-restricted CD8+ T cell response against hepatitis C virus requires compensatory mutations outside the epitope.

Authors:  Marianne Ruhl; Patrick Chhatwal; Heiko Strathmann; Thomas Kuntzen; Dorothea Bankwitz; Kathrin Skibbe; Andreas Walker; Falko M Heinemann; Peter A Horn; Todd M Allen; Daniel Hoffmann; Thomas Pietschmann; Jörg Timm
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

7.  HCV genotype-3a T cell immunity: specificity, function and impact of therapy.

Authors:  Isla S Humphreys; Annette von Delft; Anthony Brown; Linda Hibbert; Jane D Collier; Graham R Foster; Monira Rahman; Annabel Christian; Paul Klenerman; Eleanor Barnes
Journal:  Gut       Date:  2012-02-15       Impact factor: 23.059

Review 8.  Mutational escape of CD8+ T cell epitopes: implications for prevention and therapy of persistent hepatitis virus infections.

Authors:  Joerg Timm; Christopher M Walker
Journal:  Med Microbiol Immunol       Date:  2014-12-24       Impact factor: 3.402

9.  Prediction of T-cell epitopes of hepatitis C virus genotype 5a.

Authors:  Maemu P Gededzha; M Jeffrey Mphahlele; Selokela G Selabe
Journal:  Virol J       Date:  2014-11-08       Impact factor: 4.099

10.  Significance of monoclonal antibodies against the conserved epitopes within non-structural protein 3 helicase of hepatitis C virus.

Authors:  Yixin Bian; Shuoxian Zhao; Shaomei Zhu; Jinfeng Zeng; Tingting Li; Yongshui Fu; Yuanzhan Wang; Xin Zheng; Ling Zhang; Wenjing Wang; Baocheng Yang; Yuanping Zhou; Jean-Pierre Allain; Chengyao Li
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.